Malignant Hematology Overview – A 2018 Snapshot
The following graphs provide an overview of performance and quality along the malignant hematology care continuum.
Overall, Ontario’s cancer system as a whole is performing well on malignant hematology care compared with other jurisdictions and time trend data. For highlights of bright spots and opportunities to help focus efforts in improving the quality of care delivery for people with hematologic cancer, see Malignant Hematology in Ontario.
To learn more about the significant investments and advancements made to enhance malignant hematology care in Ontario, see the Special Focus story.
Future editions of the Cancer System Quality Index will include additional malignant hematologic indicators (see Indicators Under Development) to ensure the index is robust and fully represents a high-performing cancer system.
Cancer Burden
Age-standardized incidence rate
To learn more, see Cancer Incidence.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Multiple myeloma
Age-standardized 1-year survival ratio
To learn more, see Cancer Survival.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Multiple
myeloma
Age-standardized 5-year survival ratio
To learn more, see Cancer Survival.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Multiple myeloma
Treatment
Median number of days from diagnosis to start of treatment
To learn more, see Time from Diagnosis to First Treatment
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Multiple myeloma
Median number of days from remission to allogeneic transplant
To learn more, see Access to Hematopoietic Cell Transplant.
- Acute myeloid leukemia
Median number of days from second-line chemotherapy to autologous transplant
To learn more, see Access to Hematopoietic Cell Transplant.
- Diffuse large B-cell lymphoma
Median number of days from first systemic treatment to autologous transplant
To learn more, see Access to Hematopoietic Cell Transplant.
- Multiple myeloma
End-of-Life Care
Emergency department visits in last 30 days of life
To learn more, see Emergency Department Visits in the Last 30 Days of Life.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Multiple myeloma
Transfusions in last 2 weeks of life
To learn more, see Intensive Care Unit (ICU) Admissions and Transfusions in the Last 2 Weeks of Life.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Multiple Myeloma
Intensive care unit admissions in last 2 weeks of life
To learn more, see Intensive Care Unit (ICU) Admissions and Transfusions in the Last 2 Weeks of Life.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Multiple myeloma
Symbol | Indicator rating |
---|---|
![]() |
Bright spots |
![]() |
Room for improvement |
![]() |
Not rated |
Indicators without ratings
For more information on indicator ratings and approach, including indicators without ratings, see Highlights: Cancer System Performance in Ontario, 2020.